[REVISION HISTORY]

AstraZeneca stock performance and earnings

1 recorded revision of this situation.

What changed

2026-11-02 11:51 UTC → 2026-11-02 16:25 UTC · added ~~removed~~

AstraZeneca shares initially saw a slight increase of 0.2% to 118.90 GBP following reports of a 5.84% year-over-year increase in quarterly revenue. The company also noted the expansion of its breast cancer drug, Enhertu, in England. By November, the company experienced a significant upward trend, with reports noting a 7.02% increase to $186.65. Technical analysis indicated the stock broke above its 200-day moving average, signaling a recovery from previous lows despite indicators suggesting the stock was in overbought territory. As of November 2026, AstraZeneca has reiterated a long-term goal to reach $80 billion in full-year revenue by 2030. To achieve this, the company is implementing a “Reshaping for Sustainable Growth” program designed to save $1.5 billion annually. CEO Pascal Soriot stated that these savings will be reinvested into drug research, noting that artificial intelligence will play a key role in increasing operational efficiency and supporting the company’s pipeline.

Versions

Select a version to see what changed compared to the one before it.